이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

원발성 쇼그렌 증후군(pSS)이 있는 성인의 Nipocalimab에 대한 연구

2026년 10월 15일 업데이트: Janssen Research & Development, LLC

성인 원발성 쇼그렌 증후군(pSS)에 대한 니포칼리맙의 효능 및 안전성을 평가하기 위한 무작위, 위약 대조, 이중맹검, 다기관 연구

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

연구 개요

연구 유형

중재적

등록 (실제)

163

단계

  • 2 단계

확장된 액세스

일시적으로 사용할 수 없음 임상시험 외. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Leeuwarden, 네덜란드, 8934 AD
        • Medisch Centrum Leeuwarden
      • Rotterdam, 네덜란드, 3015 GD
        • Erasmus Medisch Centrum
      • Taipei, 대만, 11490
        • Tri-Service General Hospital
      • Taoyuan, 대만, 333
        • Chang Gung Memorial Hospital Linkou Branch
      • Berlin, 독일, 10117
        • Charite Universitaetsmedizin Berlin
      • Cologne, 독일, 50923
        • Uniklinik Köln
      • Dresden, 독일, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Hamburg, 독일, 20095
        • Hamburger Rheuma Forschungszentrum II
      • Kirchheim unter Teck, 독일, 73230
        • medius KLINIK KIRCHHEIM
      • Tübingen, 독일, 72076
        • Universitatsklinikum Tubingen
    • Alabama
      • Anniston, Alabama, 미국, 36207
        • Anniston Medical Clinic
    • Arizona
      • Glendale, Arizona, 미국, 85306
        • Arizona Arthritis and Rheumatology Research PLLC
      • Mesa, Arizona, 미국, 85210
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Fullerton, California, 미국, 92835
        • St. Jude Heritage Medical Group
      • Upland, California, 미국, 91786
        • Inland Rheumatology Clinical Trials, Inc.
    • Colorado
      • Denver, Colorado, 미국, 80230
        • Denver Arthritis Clinic
      • Denver, Colorado, 미국, 80228
        • Colorado Arthritis Associates
    • Florida
      • Boca Raton, Florida, 미국, 33486
        • Rheumatology Associates Of South Florida
      • Brandon, Florida, 미국, 33511
        • Bay Area Arthritis and Osteoporosis
      • Fort Lauderdale, Florida, 미국, 33309
        • Centre for Rheumatology, Immunology and Arthritis
      • Jacksonville, Florida, 미국, 32209
        • University of Florida Health Jacksonville
      • Orlando, Florida, 미국, 32835
        • Omega Research Consultants
    • Illinois
      • Gurnee, Illinois, 미국, 60031
        • Clinical Investigation Specialists
    • Iowa
      • Iowa City, Iowa, 미국, 52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Medical Center
    • Minnesota
      • Eagan, Minnesota, 미국, 55121
        • St. Paul Rheumatology P A
    • Mississippi
      • Tupelo, Mississippi, 미국, 38801
        • North Mississippi Medical Clinics
    • North Carolina
      • Salisbury, North Carolina, 미국, 28144
        • PMG Research of Salisbury
    • Pennsylvania
      • Duncansville, Pennsylvania, 미국, 16635
        • Altoona Center For Clinical Research
      • Philadelphia, Pennsylvania, 미국, 19104
        • University of Pennsylvania
    • South Carolina
      • Columbia, South Carolina, 미국, 29204
        • Columbia Arthritis Center
    • Tennessee
      • Jackson, Tennessee, 미국, 38305
        • West Tennessee Research Institute
      • Memphis, Tennessee, 미국, 38119
        • Dr. Ramesh Gupta
    • Texas
      • Austin, Texas, 미국, 78731-3146
        • Austin Regional Clinic
      • Carrollton, Texas, 미국, 75007
        • Trinity Clinical Research, LLC
      • A Coruña, 스페인, 15006
        • Hosp Univ A Coruna
      • Córdoba, 스페인, 14004
        • Hosp Reina Sofia
      • Mérida, 스페인, 6800
        • Hosp. de Merida
      • Sabadell, 스페인, 08208
        • Corporacio Sanitari Parc Tauli
      • Salamanca, 스페인, 37007
        • Hosp Clinico Univ de Salamanca
      • Seville, 스페인, 41010
        • Hosp. Infanta Luisa
      • Brescia, 이탈리아, 25123
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
      • Catania, 이탈리아, 95100
        • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
      • Milan, 이탈리아, 20132
        • IRCCS Ospedale San Raffaele
      • Palermo, 이탈리아, 90129
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Verona, 이탈리아, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Fuchū, 일본, 183 8524
        • Tokyo Metropolitan Tama Medical Center
      • Nagasaki, 일본, 852-8501
        • Nagasaki University Hospital
      • Sapporo, 일본, 060-8648
        • Hokkaido University Hospital
      • Tokyo, 일본, 104 8560
        • St. Luke's International Hospital
      • Tokyo, 일본, 173 8610
        • Nihon University Itabashi Hospital
      • Tsukuba, 일본, 305-8520
        • University of Tsukuba Hospital
      • Lisbon, 포르투갈, 1050-034
        • Instituto Portugues de Reumatologia
      • Ponte de Lima, 포르투갈, 4990-078
        • ULSAM, EPE - Hospital Conde de Bertiandos
      • Bydgoszcz, 폴란드, 85-065
        • Nasz Lekarz Przychodnie Medyczne
      • Bydgoszcz, 폴란드, 85-168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
      • Gmina Końskie, 폴란드, 26 200
        • Zespolu Opieki Zdrowotnej w Konskich
      • Krakow, 폴란드, 30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Lublin, 폴란드, 20-607
        • REUMED Zespol Poradni Specjalistycznych Filia nr 2
      • Poznan, 폴란드, 61 113
        • Centrum Medyczne
      • Warsaw, 폴란드, 00-874
        • Medycyna Kliniczna
      • Warsaw, 폴란드, 02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw, 폴란드, 03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw, 폴란드, 52 415
        • Centrum Medyczne Oporow
      • La Tronche, 프랑스, 38700
        • CHU de Grenoble Hopital Albert Michallon
      • Le Mans, 프랑스, 72037
        • Centre Hospitalier Le Mans
      • Marseille, 프랑스, 13285
        • Hopital Saint Joseph
      • Paris, 프랑스, 75013
        • Hopital Pitie Salpetriere
      • Strasbourg, 프랑스, 67098
        • CHRU Hôpital de Hautepierre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland biopsy), and was diagnosed with pSS no less than 26 weeks prior to screening
  • At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
  • At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
  • It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
  • Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
  • Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
  • Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Group 1: Placebo

Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Placebo infusion will be administered intravenously.

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

실험적: Group 2: Nipocalimab Dose 1

Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

다른 이름들:
  • JNJ-80202135
  • M281
실험적: Group 3: Nipocalimab Dose 2

Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

다른 이름들:
  • JNJ-80202135
  • M281

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
기간: Baseline (Week 0), Week 24

In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

Baseline (Week 0), Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
기간: Baseline (Week 0), Week 24

Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
기간: Baseline (Week 0), Week 24

ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
기간: Baseline (Week 0), Week 24

In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

Baseline (Week 0), Week 24
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
기간: Baseline (Week 0), Week 24

Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of >= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
기간: At Week 24

Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of >=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of >=3 in clinESSDAI score (3), (ii) decrease of >=1 point or >=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of >=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of >=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of >=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of >=25% in rheumatoid factor/decrease of >=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

At Week 24
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
기간: At Week 24

DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score * domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of >= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

At Week 24
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
기간: At Week 24

Percentage of participants with improvement from baseline in >= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in >= 3 of the following 5 categories: (i) clinESSDAI score less than (<) 5 (low disease activity), (ii) decrease of >= 1 point or >= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (<= 5 mm) and an increase of >= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of >= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of >= 25% in rheumatoid factor or decrease of >= 10% in IgG.

At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
기간: Post first administration of study intervention (Week 0) up to Week 30

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
기간: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin < 20 grams per liter (g/L) (< 2.0 grams per deciliter [g/dL]); applicable to participants who had albumin greater than (>) 20 g/L at previous assessments. Those who entered with < 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin > 20 g/L or those who entered with albumin < 20g/L and then had an increase in albumin > 20 g/L which subsequently decreased to < 20 g/L were reported as an AESI.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
기간: Post first administration of study intervention (Week 0) up to Week 30

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
기간: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Vital Signs
기간: Post first administration of study intervention (Week 0) up to Week 30

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (< 36 degree Celsius and > 38 degree Celsius), pulse rate (<= 50 beats per minute [bpm] and with >= 15 bpm decrease from baseline and >= 120 bpm and with >= 15 bpm increase from baseline), and blood pressure (systolic blood pressure [SBP]: <= 90 millimeters of mercury [mmHg] and with >= 20 mmHg decrease from baseline and >= 160 mmHg and with >= 20 mmHg increase from baseline; diastolic blood pressure [DBP]: <= 50 mmHg and with >= 15 mmHg decrease from baseline and >= 100 mmHg and with >= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
기간: Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Laboratory parameters included hematology (platelet count [platelets: decrease > 20% and value < 100)], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential [lymphocytes: decrease > 20% and value < 0.08], [leukocytes: decrease > 10% and value < 2.5], [neutrophils: increase > 30% and value > 0.90], [eosinophils: increase > 20% and value > 0.10]), serum chemistry (phosphate [decrease > 10% and value < 0.6), lipid panel (high-density lipoprotein [HDL] and low-density lipoprotein [LDL], creatine kinase: increase > 20% and value > 960, cholesterol: value >= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Serum Nipocalimab Concentration Over Time
기간: Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30

Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Change From Baseline in C-reactive Protein (CRP)
기간: Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30

Change from baseline in CRP were reported.

Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
기간: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
기간: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
기간: Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30

Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
기간: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in autoantibodies included RF were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
기간: Baseline (Week 0) up to Week 30

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
기간: Baseline (Week 0) up to Week 30

Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 9월 21일

기본 완료 (실제)

2023년 10월 23일

연구 완료 (실제)

2023년 11월 30일

연구 등록 날짜

최초 제출

2021년 7월 9일

QC 기준을 충족하는 최초 제출

2021년 7월 9일

처음 게시됨 (실제)

2021년 7월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 15일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다